NEWS CENTER

Position:

Group Announcement

Media reports

Group News

The company’s brand value has risen to the forefront of the pharmaceutical industry.

Category:

Group Announcement

Time：2019-05-24

The “2019 China Brand Value Evaluation Release and China Brand Building Summit Forum,” hosted by Xinhua News Agency, the Economic Daily, the China Council for the Promotion of International Trade, the China Brand Building Promotion Association, and the China Asset Appraisal Association, and co-organized by China Brand Magazine and other institutions, was held in Shanghai. In the “2019 Brand Value Evaluation Release List,” a total of 49 pharmaceutical and healthcare brands were listed. Among them, Shijiazhuang Sihua Pharmaceutical Co., Ltd. ranked 16th on the list with a brand strength score of 856 and a brand value of 4.646 billion yuan. Its brand value increased by 1.179 billion yuan compared to the previous year.

On May 9, the “2019 China Brand Value Evaluation Information Release and China Brand Building Summit Forum,” hosted by Xinhua News Agency, the Economic Daily, the China Council for the Promotion of International Trade, the China Brand Building Promotion Association, and the China Asset Appraisal Association, and jointly organized by China Brand Magazine and other institutions, was held in Shanghai. In the “2019 Brand Value Evaluation Information Release List,” a total of 49 pharmaceutical and healthcare brands made the list. Among them, Shijiazhuang No.4 Pharmaceutical Co., Ltd. ranked 16th with a brand strength score of 856 and a brand value of 4.646 billion yuan. Its brand value increased by 1.179 billion yuan compared to the previous year, fully demonstrating the broad recognition that the pharmaceutical market has for the Shijiazhuang No.4 Pharmaceutical brand.

This year’s release of China Brand Value Evaluation marks the sixth consecutive year that China has hosted and published such an event. In 2019, the scope of the China Brand Value Evaluation encompassed corporate brands, product brands, regional brands, technology innovation brands, and time-honored Chinese brands. Among these, corporate brands and product brands were primarily targeted at industries in China that boast industrial advantages, account for a relatively high share of the nation’s GDP, have a solid foundation for brand development, and meet mature criteria for brand evaluation. In particular, to promote traditional Chinese culture and national brands and revive the glory of time-honored brands, the “time-honored Chinese brands” category was treated as a separate section, with independent applications and evaluations. Following last year’s pilot exploration of proactive evaluation in the financial sector, this year the financial industry fully adopted proactive evaluation and expanded its scope to other sectors, covering 1,293 enterprises and 598 brands.

In recent years, Shijiazhuang No.4 Pharmaceutical Co., Ltd. has adhered to the business philosophy of "Integrity First, Quality for the People," taking the enhancement of a comprehensive quality mindset as its key driver to promote the development of both product and corporate brands, thus forging a path of quality-brand development uniquely characteristic of No.4 Pharmaceutical. The company’s flagship product, large-volume infusions, boasts a production history spanning fifty years. Over the past half-century, the company has placed great emphasis on brand building, steadfastly upholding the principle of “Quality First” and continuously exploring and striving for advancements in technology and production scale. It has taken the lead within the domestic industry by establishing a provincial-level engineering research center for large-capacity injectables, a quality-control engineering laboratory for chemical drug injections, a national-local joint laboratory for quality control of chemical drug injections, and a national enterprise technology center. The company ranks among the top in the industry in terms of R&D investment, R&D capabilities, and patent holdings. Key quality-control indicators for large-volume infusions consistently exceed the standards set forth in the National Pharmacopoeia. The product was recognized as one of Shijiazhuang City’s Top Ten Industrial Brands in 2017. Furthermore, this year, the company’s established and applied quality-control technology system for soft-packaged large-volume infusions was awarded the First Prize of the Provincial Science and Technology Progress Award.

After fifty years of brand-building, Shijiazhuang No.4 Pharmaceutical has earned a stellar reputation in both domestic and international markets. Among its products, flexible-bag intravenous solutions account for over 50% of the domestic market share. The company’s products have successfully passed six international quality certifications and audits, including those from Australia’s TGA and the Netherlands’ IDA, and are distributed not only throughout China but also to 80 countries and regions worldwide. The company has received numerous prestigious awards, such as the National High-Quality Product Award, Provincial Famous Brand Product, and Consumer-Trustworthy Product. Shijiazhuang No.4 Pharmaceutical’s “Shimen” trademark was among the first in China to be recognized as a well-known trademark in the field of large-volume intravenous solution manufacturing. Currently, the company boasts an annual production capacity of 2 billion bottles (bags) of large-volume intravenous solutions. In terms of production scale, quality standards, process technology, and brand influence, it holds a leading position within the domestic industry. The company has been ranked among the top 100 Chinese pharmaceutical enterprises in terms of overall strength and is listed among the top 10 outstanding brands in China’s chemical pharmaceutical preparations export sector. It has become a major domestic base for the production, R&D, and export of large-capacity injectables.

Chairman Qu Jiguang stated that Shijiazhuang No.4 Pharmaceutical will further accelerate its internationalization process, focusing on cultivating a group of renowned products with strong international competitiveness and high added value. The company will continue to strengthen and expand its national pharmaceutical brands, building itself into a comprehensive pharmaceutical group that integrates modernization and internationalization. Upholding the brand philosophy of being a first-class enterprise, producing first-class pharmaceuticals, and providing first-class services, Shijiazhuang No.4 Pharmaceutical will continue to propel Chinese brands onto the global stage, enabling the “Si Yao” brand to gain a foothold in international markets and better serve human health and well-being.

Keywords:

The company’s submitted speech won third prize.

The company’s 150mg fluconazole tablets are the first in China to pass the consistency evaluation.

The company’s submitted speech won third prize.

The company’s 150mg fluconazole tablets are the first in China to pass the consistency evaluation.